Business Context and Reporting Period
This Form 8-K Current Report was filed by Galectin Therapeutics Inc. on February 23, 2012. The company is incorporated in Nevada and maintains its principal executive offices in Newton, Massachusetts. The report addresses a corporate governance event occurring on the date of the report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the appointment of Kevin D. Freeman to the Audit Committee of the Board of Directors. With this appointment, the Audit Committee now consists of three members, all of whom are independent directors pursuant to NASDAQ Listing Rules.
Outlook, Risks, and Management Commentary
There is no guidance, outlook, or discussion of risks and contingencies in this filing. The document provides biographical details regarding Mr. Freeman, noting his role as CEO of Freeman Global Investment Counsel and his background in investment services.
Key Facts for Investor Verification
- Kevin D. Freeman was appointed to the Audit Committee on February 23, 2012.
- The Audit Committee now comprises three independent directors, satisfying NASDAQ Listing Rules.
- Mr. Freeman has served as a director since May 26, 2011, and is a Certified Financial Advisor.
- No financial data or operational updates are included in this specific filing.